Ignite Creation Date:
2024-05-06 @ 8:24 PM
Last Modification Date:
2024-10-26 @ 3:27 PM
Study NCT ID:
NCT06371482
Status:
RECRUITING
Last Update Posted:
2024-06-17
First Post:
2024-03-27
Brief Title:
Durvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer Camel-01
Sponsor:
Hebei Medical University Fourth Hospital
Organization:
Hebei Medical University Fourth Hospital
Study Overview
Official Title:
Durvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer
Status:
RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This trial aims to assess efficacy and safety of durvalumab combined with chemoradiotherapy for limited stage small cell lung cancer
Detailed Description:
Small cell lung cancer is a highly malignant tumor that accounts for about 15 of all lung cancer types The 5-year survival rate is less than 5 and the overall survival of patients who do not receive any antitumor therapy is only 2-4 months In the past 40 years 4 to 6 cycles of platinum-based chemotherapy that is etoposide combined with cisplatin or carboplatin has become the standard therapy for small cell lung cancer patients and has been recommended by major global tumor treatment guidelines While initial response rates are as high as 70 80 of limited-stage patients and nearly all patients with extensive stages are found to experience relapse or disease progression Current guidelines recommend that patients with limited stage small cell lung cancer adopt the EP regimen combined with thoracic radiotherapy as the preferred treatment for patients with limited stage small cell lung cancer PD-L1 is part of a complex system of receptors and ligands involved in controlling T cell activation PD-L1 acts at multiple sites in the body releasing inhibitory signals to T cells via the PD-1 and CD80 receptors to help regulate the immune response Durvalumab is an immunoglobulin G IgG 1-κsubtype monoclonal antibody mAb that blocks the interaction of PD-L1 with PD-1 in T cells and CD80 B71 in immune cells ics This trial aims to assess efficacy and safety of durvalumab combined with chemoradiotherapy for limited stage small cell lung cancer
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None